On August 19, 2025, NovaBay Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to sell preferred stock worth $6 million to David E. Lazar, which could later convert into 120 million shares of common stock. The company aims to use the proceeds for operations and to potentially declare a special dividend by the fourth quarter of 2025, following stockholder approval.